Sudeep Pharma Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹563 - ₹593
- Lot size
- 25 shares
- Issue amount
- ₹895 cr
- Total subscription
- 93.72×
- Opens
- 21 Nov 2025
- Closes
- 25 Nov 2025
- Allotment
- 26 Nov 2025
- Listing
- 28 Nov 2025
Offer at a glance
Issue overview
- Issue size
- 1,50,92,749 shares
- Face value
- ₹1 Per Share
- Minimum investment
- ₹14,075
- Fresh issue
- ₹95 cr
- Offer for sale
- ₹800 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,825
- Issue type
- Bookbuilding IPO
- Shares before issue
- 11,13,46,602
- Shares after issue
- 11,29,48,626
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 25 | ₹14,825 |
| sHNI | 14 | 350 | ₹2,07,550 |
| bHNI | 68 | 1,700 | ₹10,08,100 |
Share reservation
Subscription & GMP
Subscription by category
Reported 25 Nov 2025
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 2,11,298 | 27,22,863 |
| HNIs(10L +) | 4,312 | 1,17,655 |
| HNIs (2-10L) | 2,156 | 1,64,607 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 179 | 38,141.08 |
| FIIs | 0 | 11,221.95 |
| FIs | 0 | 15,279.16 |
| Mutual Funds | 0 | 1,698.7 |
| Others | 0 | 9,941.26 |
| RETAIL | 313.25 | 4,902.41 |
| HNIs 2+ | 44.75 | 3,594.84 |
| HNIs 10+ | 89.5 | 12,074.65 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Jun-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 0 | 0 | 0 | 0 |
| ROE | 4.52 | 28.13 | 37.41 | 27.91 |
| ROCE | 5.5 | 29.82 | 41.17 | 29.4 |
| RONW | 0 | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 47.61 | 0 | 0 |
| POST IPO(PE) | 53.55 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Sudeep Pharma Limited, incorporated in 1989, is a global manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, supplying over 200 products to customers in more than 100 countries. The company operates six manufacturing facilities with a total capacity of 50,000 MT, producing key minerals such as calcium, iron, magnesium, zinc, potassium, and sodium. With strong in-house R&D and pilot-scale labs, the company focuses on developing high-quality mineral salts and excipients across its pharmaceutical, food and nutrition, specialty ingredients, and triturates product segments. As of December 31, 2024, it employed 704 permanent staff.
Strengths
- Strong Market Leadership with a Wide Product Range: A leading manufacturer of pharmaceutical, food, nutrition, and specialty ingredients (as of June 30, 2025), with strong expertise in mineral-based products, iron phosphate, and a broad portfolio of specialty food ingredients such as encapsulated preservatives.
- Advanced and Fully Compliant Manufacturing Setup: Operates four manufacturing facilities with 12 production lines across Gujarat and Ireland, covering 68,446 sq. meters and offering an annual capacity of 72,246 MT, ensuring efficient production and regulatory compliance.
- Innovation Driven by Strong R&D Capabilities: Equipped with two R&D centers and a team of 41 specialists focusing on particle engineering, shelf-life enhancement, nutrient bioavailability, and advanced formulation solutions, supported by modern equipment to drive technology improvements, sustainability, and product expansion.
Risk factors
- High Dependence on Key Customers: A major share of revenue is concentrated among a limited set of customers, making the business vulnerable to reduced orders or the loss of any key client, which could impact financial performance and cash flow.
- Strict Regulatory and Quality Compliance Requirements: Manufacturing units are regularly inspected and must meet standards prescribed by global agencies such as USFDA, EXCiPACT, FSSC, WHO-GMP, ISO, and HACCP. Any deviation, quality lapse, or non-compliance could lead to regulatory action and harm the company’s reputation.
- Risk of Operational Disruptions: Manufacturing and R&D activities face potential threats from equipment breakdowns, industrial accidents, regulatory issues, natural calamities, or outbreaks of infectious diseases. Any disruption or shutdown could negatively affect business operations, financial results, and liquidity.
Promoters
Sujit Jaysukh Bhayani
Avani Sujit Bhayani
Shanil Sujit Bhayani
Sujeet Jaysukh Bhayani HUF
Riva Resources Private Limited
Bhayani Family Trust
Registrar & documents
Lead manager
ICICI Securities Limited, IIFL Capital Services Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340
+91 265 284 0656
[email protected]Company website ↗Understanding SUDEEPPHRM IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.